



Enhancing Excitation To Combat Lost Silencing: Therapeutic Considerations For Rett Syndrome

SEMINAR & VISITING SPEAKER SERIES

DATE

Friday, February 10th, 2017
12:00 pm

LOCATION

Apotex Theatre 071

SPEAKER

Dr. James Eubanks

Senior Scientist - Krembil Research Institute
Professor - Department of Surgery,
University of Toronto

BIO:

The primary interests of my group relate to defining how the absence of either methyl DNA binding factor MeCP2, or more recently CDKL5, affects normal brain function and/or alters the normal progression of brain development, and to identifying strategies that can be used to correct the observed alterations. Our work encompasses generating novel transgenic mouse lines that can be used to address questions relating to our focus, to testing novel pharmacological agents in established models of Rett syndrome as part of translational efforts. We are well positioned to assess therapeutically meaningful endpoints for the translational studies, and have the skills needed to identify key deficits that can then be subsequently targeted. It is our intention to identify novel strategies that can someday be employed to treat patients with Rett syndrome, with the ultimate goal being condition correction. Our current investigations span several research disciplines, including cell biology, pharmacology, electrophysiology, molecular genetics, animal behavior, and live cell imaging.

For more information:

T: 204-235-3939

E: Networking@manitobaneuroscience.ca